Pain and cannabinoids: Science and evidence

Pain Reviews

Volumn 9, Issue 1, 2002, Pages 41-67

  Farquhar Smith, W Paul ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ADENYLATE CYCLASE; ANALGESIC AGENT; ANANDAMIDE; BENZOPYRANOPERIDINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL DERIVATIVE; CANNABIS; CODEINE; DEXANABINOL; DOCOSATETRAENOYLETHANOLAMIDE; DRONABINOL; FATTY ACID AMIDASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HERBACEOUS AGENT; ION CHANNEL; LEVONANTRADOL; MORPHINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NOLADIN ETHER; NONSTEROID ANTIINFLAMMATORY AGENT; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; CANCER PAIN; HUMAN; HYPERALGESIA; INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTOPERATIVE PAIN; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THOUGHT DISORDER; VERTIGO; VISCERAL PAIN;

EID: 0344823856     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: 10.1191/0968130202pr188ra     Document Type: Review

References (194)

1. Iversen L. The science of marijuana. Oxford: Oxford University Press, 2000.
2. Mechoulam R, Hanuš L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000; 108: 1-13.
3. Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobiol Dis 1998; 5: 447-61.
4. Rice ASC. Cannabinoids and pain. Curr Opin Invest Drugs 2001; 2: 399-414.
5. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-47.
6. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-64.
8. Devane WA, Hanuš L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-49.
9. Munro S, Thomas KL, Abu Shaar K. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
10. Galiegue S, Mary S, Marchand J et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
11. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279: 129-34.
12. Onaivi ES, Chakrabarti A, Chaudhuri G. Cannabinoid receptor genes. Prog Neurobiol 1996; 48: 275-305.
13. Shire D, Carillon C, Kaghad M et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995; 270: 3726-31.
14. 1 receptor isoforms. J Pharmacol Exp Ther 1996; 278: 871-78.
15. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
16. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318.
17. Mailleux P, Parmentier M, Vanderhaeghen JJ. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 1992; 143: 200-204.
18. Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993; 327: 535-50.
19. 1. J Comp Neurol 2000; 422: 159-71.
20. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
21. Sullivan JM. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learning Memory 2000; 7: 132-39.
22. 1 cannabinoid receptor in the primate spinal cord. J Neurocytol 2000; 28: 39-45.
23. 1 receptor expression in rat spinal cord. Mol Cell Neurosci 2000; 15: 510-21.
24. 1 cannabinoid receptors. Life Sci 1999; 65: 597-605.
25. Friedel RH, Schnurch H, Stubbusch J, Barde Y. Identification of genes differentially expressed by nerve growth factor and neurotrophin-3-dependent sensory neurones. Proc Natl Acad Sci U S A 1997; 94: 12670-75
26. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92: 1171-75.
27. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25.
28. 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridisation study. Neuroscience 1999; 90: 923-31.
29. 1 receptor is localised predominantly on N52 positive neurones within the dorsal root ganglion [Abstract]. Soc Neurosci Abstr 2001; 27: 716.3.
30. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid I receptors are expressed in nociceptive primary sensory neurones. Neuroscience 2000; 100: 685-88.
31. Ross RA, Coutts AA, McFarlane SM et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 2001; 40: 221-32.
32. 1 receptors. Pain 1998; 75: 111-19.
33. Farquhar-Smith WP, Rice ASC. A neuro-immune mechanism in cannabinoid-mediated attenuation of nerve growth factor (NGF)-induced hyperalgesia. Anesthesiology 2003 (in press).
34. Calignano A, La Rana G, Guiffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-81.
35. Nackley AG, Suplita RL, Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003; 117: 659-70.
36. Matsuda LA. Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 1997; 11: 143-66.
37. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 1999; 65: 637-44.
38. 2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997; 142: 278-87.
39. Walter L, Franklin A, Witting A et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003; 23: 1398-405.
40. Skaper SD, Buriani A, Dal Toso R et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurones. Proc Natl Acad Sci U S A 1996; 93: 3984-89.
41. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93: 239-45.
42. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998; 285: 285-92.
43. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 1998; 286: 1301-308.
44. Welch SP, Dunlow LD, Patrick GS, Razdan RK. Characterisation of anandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J Pharmacol Exp Ther 1995; 273: 1235-44.
45. 1 receptor knockout mice. Proc Natl Acad Sci U S A 1999; 96: 5780-85.
46. 2 receptor mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44.
47. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155-63.
48. Lambert DM, Vandevoorde S, Jonsson K, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002; 9: 663-74.
49. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur J Pharmacol 2001; 419: 191-98.
50. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 1993; 90: 7656-60.
51. 2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278: 989-99.
52. Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonylglycerol. Chem Phys Lipids 2000; 108: 53-70.
53. Petitet F, Jeantaud B, Capet M, Doble A. Interaction of brain cannabinoid receptors and guanine nucleotide binding protein. Biochem Pharmacol 1997; 54: 1267-70.
54. Breivogel CS, Selley DE, Childers SR. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 1998; 273: 16865-73.
55. 1 receptor agonists in the mouse brain. Eur J Pharmacol 1997; 336: 295-98.
56. 1 receptor-G protein association. Eur J Biochem 2001; 268: 499-505.
57. 1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol Pharmacol 1998; 53: 504-10.
58. Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998; 51: 173-87.
59. Breivogel CS, Sim LJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 1997; 282: 1632-42.
60. Childers SR, Sexton T, Roy MB. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 1994; 47: 711-15.
61. Hillard CJ, Manna S, Greenberg MJ et al. Synthesis and characterisation of potent and selective agonists of the neuronal cannabinoid receptor. J Pharmacol Exp Ther 1999; 289: 1427-33.
62. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonoyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 2000; 57: 1045-50.
63. Taiwo YO, Bjerknes LK, Goetzl EJ, Levine JD. Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 1989; 32: 577-80.
64. Aley KO, Levine JD. Role of protein kinase A in the maintenance of inflammatory pain. J Neurosci 1999; 19: 2181-86.
65. Nakamura A, Fujita M, Shiomi H. Involvement of endogenous nitric oxide in the mechanism of bradykinin-induced peripheral hyperalgesia. Br J Pharmacol 1996; 117: 407-12.
66. Taiwo YO, Heller PH, Levine JD. Mediation of serotonin hyperalgesia by the cAMP second messenger system. Neuroscience 1992; 48: 479-83.
67. 2 receptors. Mol Pharmacol 1995; 48: 443-50.
68. 1 receptor. J Neurosci 1997; 17: 5327-33.
69. 1 receptor. Eur J Pharmacol 1999; 374: 445-55.
70. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992; 89: 3825-29.
71. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N 18 neuroblastoma cells. Mol Pharmacol 1993; 44: 498-503.
72. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995; 15: 6552-61.
73. Wu L, Saggau P. Presynaptic inhibition of elicited neurotransmitter release. Trends Neurol Sci 1997; 20: 204-12.
74. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 1993; 61: 352-55.
75. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270: 219-27.
76. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993; 231: 313-14.
77. Slipetz DM, O'Neill GP, Favreau L et al. Activation of human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 1995; 48: 352-61.
78. Fride E, Barg J, Levy R et al. Low doses of anandamide inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1995; 272: 699-707.
79. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995; 92: 3376-80.
80. Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-57.
81. Szolcsanyi J. Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci 2000; 21: 41-42.
82. Di Marzo V, Bisogno T, De Petrocellis L. Anandamide: some like it hot. Trends Pharmacol Sci 2001; 22: 346-49.
83. Mechoulam R, Ben-Shabat S, Hanuš L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
84. Sugiura T, Kondo S, Sukagawa A et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
85. Di Marzo V. 2-Arachidonoyl-glycerol as an 'endocannabinoid': limelight for a formerly neglected metabolite. Biochemistry (Mosc) 1998; 63: 13-21.
86. Ben-Shabat S, Fride E, Sheskin T et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonyl-glycerol cannabinoid activity. Eur J Pharmacol 1998; 353: 23-31.
87. Baker D, Pryce G, Croxford JL et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2000; 15: 300-302.
88. 2 cannabinoid receptor. J Pharmacol Exp Ther 2000; 292: 886-94.
89. 1 receptor. Proc Natl Acad Sci U S A 2001; 98: 3662-65.
90. Walter L, Franklin A, Witting A, Moller T, Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 2002; 277: 20869-76.
91. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993; 46: 791-96.
92. Di Marzo V, Fontana A, Cadas H et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-91.
93. Kondo S, Sugiura T, Kodaka T, Kudo N, Waku K, Tokumura A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch Biochem Biophys 1998; 354: 303-10.
94. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997; 272: 3315-23.
95. Guhring H, Hamza M, Sergejeva M et al. A role for endocannabinoids in indomethicin-induced spinal antinociception. Eur J Pharmacol 2003; 454: 153-63.
96. Piomelli D, Beltramo M, Giuffrida A. Endogenous cannabinoid signaling. Neurobiol Dis 1998; 5: 462-73.
97. Guiffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci 1999; 2: 358-63.
98. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-92.
99. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarised postsynaptic neurons to presynaptic terminals. Neuron 2001; 29: 729-38.
100. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001; 29: 717-27.
101. Di Marzo V, Deutsch DG. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 1998; 5: 386-404.
102. Jacobsson SOP, Fowler CJ. Characterization of palmitoylethanolamide transport in mouse neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 2001; 132: 1743-54.
103. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1998; 277: 1094-97.
104. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998; 1392: 153-75.
105. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterisation of an enzyme that degrades fatty acid amides. Nature 1996; 384: 83-87.
106. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolase. Proc Natl Acad Sci U S A 1997; 94: 2238-42.
107. Tiger G, Stenstrom A, Fowler CJ. Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate. Biochem Pharmacol 2000; 59: 647-53.
108. Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effects of anadamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther 1997; 283: 1138-43.
109. Fowler CJ, Tiger G, Stenstrom A. Ibuprofen inhibits rat brain deamination of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J Pharmacol Exp Ther 1997; 283: 729-34.
110. Fowler CJ, Janson U, Johnson RM et al. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and fluriprofen. Arch Biochem Biophys 1999; 362: 191-96.
111. Cravatt BF, Demarest K, Patrichelli MP et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, Proc Natl Acad Sci U S A 2001; 98: 9371-76.
112. Ashton CH. Therapeutic uses of cannabis. Amsterdam: British Medical Association/Harwood, 1997.
113. Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualititative systematic review. Lancet 2001; 323: 13-16.
114. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64.
115. Pertwee RG, Gibson TM, Stevenson LA et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol 2000; 129: 1577-84.
116. 1 cannabinoid receptors. Biochem Biophys Res Commun 1999; 262: 275-84.
117. Rinaldi-Carmona M, Barth F, Heaulme M et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Fed Eur Biochem Sci 1994; 350: 240-44.
118. 1 receptor. Eur J Pharmacol 1997; 334: R1-2.
119. 2 receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
120. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319: R3-4.
121. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998; 18: 451-57.
122. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res 1998; 813: 323-28.
123. Smith FL, Fujimori K, Lowe J, Welch SP. Characterisation of delta-9 THC and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998; 60: 183-91.
124. Beaulieu P, Bisogno T, Punwar S et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 2000; 396: 85-92.
125. Di Marzo V, Melck D, De Petrocellis L, Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat 2000; 61: 43-61.
126. 1 receptor knockout mice. Science 1999; 283: 401-404.
127. 2-eh noradrenergic mechanism. Brain Res 1991; 559: 309-14.
128. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-94.
129. Reche I, Fuentes JA, Ruiz Gayo M. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 1996; 301: 75-81.
130. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphine, but not N,N-dially-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 1993; 265: 633-40.
131. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine. J Pharmacol Exp Ther 1992; 262: 10-18.
132. Pugh G, Smith PB, Dombrowski DS, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996; 279: 608-16.
133. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848: 183-90.
134. Gardell LR, Ossipov M, Vanderah TW, Lai J, Porreca F. Dynorphin-independent spinal cannabinoid antinociception. Pain 2002; 100: 243-48.
135. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395: 381-83.
136. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
137. Martin BR, Jefferson R, Winckler R et al. Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. J Pharmacol Exp Ther 1999; 290: 1065-79.
138. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991; 258: 517-23.
139. Hohmann AG, Martin WJ, Tsou K, Walker JM. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN55,212-2. Life Sci 1995; 56: 2111-18.
140. Hohmann AG, Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett 1998; 257: 119-22.
141. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal grey involvement. J Pharmacol Exp Ther 1996; 276: 585-93.
142. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 1996; 16: 6601-11.
143. Raffa RB, Stone DJJ, Hipp SJ. Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. Neurosci Lett 2000; 263: 29-32.
144. Dubuisson D, Dennis SG. The formalin test: a quantitive study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats. Pain 1977; 4: 161-74.
145. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitisation and persistent nociception after formalin-induced tissue injury. J Neurosci 1992; 12: 3665-70.
146. Dickenson AH, Sullivan JM. Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain 1987; 30: 349-60.
147. Tsou K, Lowitz KA, Hohmann AG et al. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 1996; 70: 791-98.
148. 8-THC-11-OIC acid (CT3) in mice. Life Sci 1998; 63: 161-68.
149. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189-99.
150. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 2002; 135: 181-87.
151. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are antiallodynic in rats with persistent inflammation. Pain 1999; 82: 199-205.
152. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345: 145-53.
153. Li J, Daughters RS, Bullis C et al. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999; 81: 25-33.
154. Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001; 93: 303-15.
155. Ko MC, Woods JH. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berl) 1999; 143: 322-26.
156. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 2001; 96: 253-60.
157. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996; 300: 227-36.
158. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993; 39: C145-47.
159. Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agro A, Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett 2000; 468: 176-80.
160. Rice ASC, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 243-56.
161. Farquhar-Smith WP, Rice ASC. The effect of endocannabinoids on peripheral NGF-induced neutrophil accumulation in rat skin. In: Proceedings of a Symposium on the Cannabinoids: 2001 Jun 27-30; San Lorenzo de El Escorial, Spain. Burlington, VT: International Cannabinoid Research Society, 2001: 76.
162. Perkins MN, Tracey DJ. Hyperalgesia due to nerve injury: role of neutrophils. Neuroscience 2000; 100: 745-57.
163. McMahon SB. Are there fundamental differences in the peripheral mechanisms of visceral and somatic pain? Behav Brain Sci 1997; 20: 381-91.
164. McMahon SB, Abel C. A model for the study of visceral pain states: chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals. Pain 1987; 28: 109-27.
165. McMahon SB. Neuronal and behavioural consequences of chemical inflammation of rat urinary bladder. Agents Actions 1988; 25: 231-33.
166. McMahon SB, Koltzenburg M. Changes in the afferent innervation of the inflamed urinary bladder. In: Mayer EA, Raybould H eds. Basic and clinical aspects of chronic abdominal pain. Amsterdam: Elsevier, 1993: 155-72.
167. Birder LA, de Groat WC. Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat. J Neurosci 1992; 12: 4878-89.
168. Jaggar SI, Scott HCF, Rice ASC. Inflammation of the rat urinary bladder is associated with a referred hyperalgesia which is NGF dependent. Br J Anaesth 1999; 83: 442-48.
169. Farquhar-Smith WP, Rice ASC. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 2001; 94: 507-13.
170. 2-like receptors. Pain 2002; 97: 11-21.
171. Dmitrieva N, McMahon SB. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 1996; 66: 87-97.
172. Dmitrieva N, Shelton D, Rice ASC, McMahon SB. The role of nerve growth factor in a model of visceral inflammation. Neuroscience 1997; 78: 449-59.
173. McMahon SB, Armanini MP, Ling LH, Phillips HS. Expression and coexpression of trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets. Neuron 1994; 12: 1161-71.
174. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anaesth 2001; 87: 12-26.
175. Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin. Neurosci Lett 1998; 252: 13-16.
176. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-60.
177. Bridges D, Ahmad K, Rice ASC. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133: 586-94.
178. 1 receptor in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92: 91-100.
179. Noyes R, Baram DA. Cannabis and analgesia. Compr Psychiatry 1974; 15: 531-35.
180. Grinspoon L, Bakalar JB. Marihuana: the forbidden medicine. New Haven, CT: Yale University Press, 1993.
181. Hill SY, Schwin R, Goodwin DW, Powell BJ. Marijuana and pain. J Pharmacol Exp Ther 1974; 188: 415-18.
182. Hill SY, Goodwin DW, Schwin R, Powell BJ. Marijuana: CNS depressant or excitant? Am J Psychiatry 1974; 131: 313-15.
183. Clark WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of marijuana on thermal pain: a sensory decision analysis. J Clin Pharmacol 1981; 21: 299S-310S.
184. Regelson W, Butler JR, Schulz J et al. Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite stimulating agent in advanced cancer patients. In: Braude MC, Szara S eds. The pharmacology of marijuana. New York: Raven Press, 1976: 763-76.
185. Noyes R, Brunk SF, Avery DAH, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84-89.
186. Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139-43.
187. Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.
188. Staquet M, Gantt C, Machin D. Effect of a nitrogen analogue of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.
189. Jain AK, Ryan JE, McMahan FG, Smith G. Evaluation of intra-muscular levonantradol in acute post operative pain. J Clin Pharmacol 1981; 21: 3205-65.
190. Boseley S. Research casts doubt on cannabis benefits. The Guardian 2001 July 6. Retrieved 28 August 2003 from: http://www.guardian.co.uk_news/story/0,3604,517557,00.html
191. Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. 1998; 9th Report Session: HL Paper 151. Retrieved 23 August 2003 from: http://www.publications parliament.uk/pa/1d200001/1dselect/1dsctech/50/5002.htm
192. Select Committee on Science and Technology, House of Lords. Cannabis: the scientific and medical evidence: 9. London: Stationery Office, 1998.
193. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
194. Rice ASC, Farquhar-Smith WP, Bridges D, Brooks J. Cannabinoids and pain. In: Dostrovsky JO, Carr DB, Kolzenburg M eds. Proceedings of the 10th World Congress on Pain (Progress in pain research and management, vol. 24); 2002 Aug 17-22; San Diego, CA, USA. Seattle: IASP Press, 2003: 437-68.